- Home
- CIGL vs MRSN Comparison
CIGL vs MRSN Comparison
Compare CIGL & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIGL
- MRSN
- Stock Information
- Founded
- CIGL 1997
- MRSN 2001
- Country
- CIGL Singapore
- MRSN United States
- Employees
- CIGL N/A
- MRSN N/A
- Industry
- CIGL Diversified Commercial Services
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- CIGL Consumer Discretionary
- MRSN Health Care
- Exchange
- CIGL Nasdaq
- MRSN Nasdaq
- Market Cap
- CIGL 46.7M
- MRSN 47.1M
- IPO Year
- CIGL 2025
- MRSN 2017
- Fundamental
- Price
- CIGL $2.62
- MRSN $10.90
- Analyst Decision
- CIGL
- MRSN Strong Buy
- Analyst Count
- CIGL 0
- MRSN 3
- Target Price
- CIGL N/A
- MRSN $33.00
- AVG Volume (30 Days)
- CIGL 3.1M
- MRSN 63.2K
- Earning Date
- CIGL 09-29-2025
- MRSN 11-12-2025
- Dividend Yield
- CIGL N/A
- MRSN N/A
- EPS Growth
- CIGL N/A
- MRSN N/A
- EPS
- CIGL N/A
- MRSN N/A
- Revenue
- CIGL $11,072,733.00
- MRSN $34,769,000.00
- Revenue This Year
- CIGL N/A
- MRSN N/A
- Revenue Next Year
- CIGL N/A
- MRSN N/A
- P/E Ratio
- CIGL N/A
- MRSN N/A
- Revenue Growth
- CIGL 6.32
- MRSN 16.14
- 52 Week Low
- CIGL $1.40
- MRSN $5.21
- 52 Week High
- CIGL $31.06
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- CIGL N/A
- MRSN 81.85
- Support Level
- CIGL N/A
- MRSN $7.83
- Resistance Level
- CIGL N/A
- MRSN $10.32
- Average True Range (ATR)
- CIGL 0.00
- MRSN 0.64
- MACD
- CIGL 0.00
- MRSN 0.25
- Stochastic Oscillator
- CIGL 0.00
- MRSN 94.53
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.